August 19, 2020 Kronos Bio Appoints Dr. Yasir Al-Wakeel as Chief Financial Officer and Head of Corporate Development
July 16, 2020 Kronos Bio and Gilead Sciences Enter Into Asset Purchase Agreement for Gilead’s SYK Inhibitor Portfolio
December 19, 2019 Harvard taps Tishman Speyer to manage first phase of its new 36-acre research campus — and biotechs can’t wait
December 19, 2019 UroGen Pharma Announces FDA Filing Acceptance and Priority Review of U.S. New Drug Application (NDA) for UGN-101
November 20, 2019 Kronos Bio Appoints Biopharma Industry Veteran Jorge F. DiMartino, M.D., Ph.D., as Chief Medical Officer
November 11, 2019 UroGen Pharma Announces Exclusive License Agreement with Agenus Inc to Advance Treatment of Urinary Tract Cancers
November 6, 2019 Allogene Therapeutics Announces Pre-Clinical Data Presentations Supporting AlloCAR T™ Pipeline at 61st American Society of Hematology Annual Meeting
November 5, 2019 Allogene Therapeutics and Notch Therapeutics Announce Collaboration to Research and Develop Induced Pluripotent Stem Cell (iPSC)-Derived Allogeneic Therapies for Hematologic Cancer Indications
September 24, 2019 UroGen Reports Positive Data from Two Important Studies: UGN-101 OLYMPUS Pivotal Trial in LG UTUC and UGN-102 Phase 2b OPTIMA II Trial in LG Bladder Cancer
September 24, 2019 UroGen Investor Day Details Positive Clinical Updates, UGN-101 Launch Preparedness, and Pipeline Advances
September 19, 2019 Allogene Therapeutics Enters Research Collaboration Directed at Enhancing Future Cancer Immunotherapies
August 7, 2019 Kronos Bio Expands Scientific Advisory Board with Addition of Roger D. Kornberg, Ph.D.
August 5, 2019 Allogene Therapeutics Appoints Rafael G. Amado, M.D. as Executive Vice President of Research and Development and Chief Medical Officer
July 16, 2019 Tishman Speyer and Bellco Capital Launch Breakthrough Properties, a First-of-Its-Kind Global Life Sciences Real Estate Platform
June 4, 2019 Allogene Therapeutics Announces FDA Clearance of the IND for ALLO-715, a BCMA Allogeneic CAR T (AlloCAR T™) Therapy
April 15, 2019 Allogene Therapeutics Announces Publication of Preclinical Study Results in Molecular Therapy Highlighting Potential for ALLO-715 (an Anti-BCMA AlloCAR T™ Therapy) in Multiple Myeloma
January 28, 2019 Allogene Therapeutics, in Collaboration with Servier, Announces FDA Clearance of the IND for ALLO-501, an anti-CD19 Allogeneic CAR T (AlloCAR T™) Therapy
January 8, 2019 UroGen Pharma Announces Positive Results of UGN-101 from Pivotal Phase 3 OLYMPUS Trial for the Non-Surgical Treatment of Patients with Low-Grade Upper Tract Urothelial Cancer (LG UTUC)
January 3, 2019 UroGen Pharma Appoints Elizabeth (Liz) Barrett as President and Chief Executive Officer
December 4, 2018 Allogene Therapeutics Presents Data from Preclinical Study of ALLO-715 (anti-BCMA) Demonstrating Allogeneic CAR T Potential in Multiple Myeloma at the 2018 ASH Annual Meeting
November 28, 2018 Kronos Bio Appoints Philip Gutry as Chief Business Officer to Expand Pipeline Opportunities
October 15, 2018 Allogene Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
